Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1302 - Safety of lorlatinib in subgroups of patients from a phase 1/2 trial

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Enriqueta Felip

Citation

Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260

Authors

E. Felip1, B.J. Solomon2, B. Besse3, T.M. Bauer4, R.A. Soo5, D..R. Camidge6, R. Chiari7, A. Bearz8, C. Lin9, S.M. Gadgeel10, E. Tan11, T. Seto12, G.R. Oxnard13, G. Peltz14, A. Abbattista15, H. Thurm16, F. Toffalorio15, S.I. Ou17, A.T. Shaw18

Author affiliations

  • 1 Oncology Department, Vall d’Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 2 Department Of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne/AU
  • 3 Department Of Medicine, Gustave Roussy Cancer Campus; Paris-Sud University, Villejuif; Orsay/FR
  • 4 Medical Oncology Department, Sarah Cannon Cancer Research Institute/Tennessee Oncology, Nashville/US
  • 5 Haematology-oncology Department, National University Hospital Singapore, Singapore/SG
  • 6 Medical Oncology Department, University of Colorado, Aurora/US
  • 7 Department Of Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia/IT
  • 8 Department Of Medical Oncology, National Institute for Cancer Research, Aviano/IT
  • 9 Department Of Oncology, National Taiwan University Hospital, Taipei/TW
  • 10 Medical Oncology Department, Rogel Cancer Center; University of Michigan, Ann Arbor/US
  • 11 Department Of Medical Oncology, National Cancer Center, Singapore/SG
  • 12 Department Of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka/JP
  • 13 Department Of Medicine, Dana-Farber Cancer Institute, Boston/US
  • 14 Worldwide Safety Oncology, Pfizer Oncology, Groton/US
  • 15 Pfizer Global Oncology Product Development-oncology, Pfizer Oncology, Milan/IT
  • 16 Pfizer Global Oncology Product Development-oncology, Pfizer Oncology, La Jolla/US
  • 17 Hematology/oncology Department, University of California Irvine, Irvine/US
  • 18 Hematology/oncology Department, Massachusetts General Hospital, Boston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1302

Background

Lorlatinib, a potent, brain-penetrant 3rd-generation (gen) ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved for the treatment of patients (pts) with ALK+ metastatic NSCLC whose disease has progressed on 2nd-gen ALK TKIs. The safety profile of lorlatinib has been previously reported; treatment-related adverse events (AEs) were primarily mild–moderate in severity and manageable through dose modification or standard medical therapy. Here, we report safety data in key subgroups of pts based on age, gender and race.

Methods

This analysis was based on 295 pts with ALK+ or ROS1+ advanced NSCLC, ± CNS metastases, enrolled in the ongoing ph 1/2 trial (NCT01970865) who received lorlatinib 100 mg once daily. All causality AEs were graded per CTCAE v4.03. Data cutoff was 02 Feb 2018.

Results

Of the 295 pts, 241 were aged <65 years (y) and 54 were ≥65 y. AEs were reported at frequencies of 99.6% and 100% in the <65 y and ≥65 y subgroups respectively; however, there were generally more AEs in the ≥65 y subgroup, e.g. anemia (<65 y: 13.7% vs ≥ 65 y: 25.9%), edema (51.5% vs 68.5%), cognitive effects (26.1% vs 40.7%), dyspnea (25.7% vs 37.0%) and fatigue (26.6% vs 35.2%). AEs were generally balanced between males (n = 125) and females (n = 170). Among Asian (n = 108) and non-Asian (n = 161) pts, AEs were reported at a similar incidence (99.1% vs 100%). Grade 3/4 and grade 5 AEs were reported, respectively, in 57.4% and 12.0% of Asian pts and 58.4% and 14.9% of non-Asian pts. There were generally more AEs in non-Asian pts (Table). With multiple dosing, there were no substantial differences in lorlatinib plasma exposure in Asian vs non-Asian pts and neither steady-state AUC nor Cmax met the threshold for dose-adjustment.Table:

1542P

Racea
AEs with >10% difference between groups, n (%)Asian (n = 108)Non-Asian (n = 161)
Hypertriglyceridemiab82 (75.9)92 (57.1)
Edemab52 (48.1)97 (60.2)
Peripheral neuropathyb41 (38.0)82 (50.9)
Cognitive effectsb18 (16.7)53 (32.9)
Weight increased15 (13.9)46 (28.6)
Mood effectsb13 (12.0)45 (28.0)
Fatigueb8 (7.4)59 (36.6)
Anemia7 (6.5)35 (21.7)
Pain in extremity7 (6.5)30 (18.6)

AEs reported in descending order of frequency in Asian pts.

a

Unspecified race (n = 26)

b

Clustered term comprising AEs that represent similar clinical symptoms/syndromes.

.

Conclusions

There were no clinically relevant differences in the AEs based on age or gender. The frequencies of most AEs known to be associated with lorlatinib were generally lower in Asian than in non-Asian pts; however, hypertriglyceridemia was more frequently reported in Asian vs non-Asian pts.

Clinical trial identification

NCT01970865.

Editorial acknowledgement

Jade Drummond of inScience Communications, Springer Healthcare (Chester, UK); funded by Pfizer Inc.

Legal entity responsible for the study

Pfizer Inc.

Funding

Pfizer Inc.

Disclosure

E. Felip: Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Boehringer Ingelheim; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: Guardant Health; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: AbbVie; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck Sharp & Dohme; Research grant / Funding (institution): Fundación Merck Salud; Research grant / Funding (institution): EMD Serono. B.J. Solomon: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy: Eisai; Licensing / Royalties: Veristrat (Biodesix); Licensing / Royalties: UpToDate; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Institution: Merck Sharp & Dohme; Advisory / Consultancy, Research grant / Funding (institution), Institution: Pfizer; Advisory / Consultancy, Institution: Genentech. B. Besse: Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): Onxeo; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Inivata; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Biogen; Research grant / Funding (institution): Blueprint Medicines; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Merck; Research grant / Funding (institution): MSD Oncology; Research grant / Funding (institution): Nektar; Research grant / Funding (institution): PharmaMar; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Spectrum Pharmaceuticals; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Tiziana Therapeutics. T.M. Bauer: Full / Part-time employment: Tennessee Oncology; Full / Part-time employment: Sarah Cannon Research Institute; Advisory / Consultancy: Guardant Health; Advisory / Consultancy, Research grant / Funding (institution): Loxo Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy, Institution: Ignyta; Advisory / Consultancy, Institution: Moderna Therapeutics; Research grant / Funding (institution): Daiichi Sankyo; Research grant / Funding (institution): Medpacto, Inc.; Research grant / Funding (institution): Incyte; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Leap Therapeutics; Research grant / Funding (institution): MabVax; Research grant / Funding (institution): Stemline Therapeutics; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Eli Lilly; Research grant / Funding (institution): GlaxoSmithKline; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Deciphera; Research grant / Funding (institution): Merrimack Pharmaceuticals; Research grant / Funding (institution): Immunogen; Research grant / Funding (institution): Millennium Pharmaceuticals; Research grant / Funding (institution): Calithera Biosciences; Research grant / Funding (institution): Kolltan Pharmaceuticals; Research grant / Funding (institution): Principa Biopharma; Research grant / Funding (institution): Peleton; Research grant / Funding (institution): Immunocore; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Aileron Therapeutics; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Amgen; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Five Prime Therapeutics; Research grant / Funding (institution): Jacobio; Research grant / Funding (institution): Top Alliance BioScience; Research grant / Funding (institution): Janssen Pharmaceuticals; Research grant / Funding (institution): Clovis Oncology; Research grant / Funding (institution): Takeda; Research grant / Funding (institution): Karyopharm Therapeutics; Research grant / Funding (institution): Onyx Pharmaceuticals; Research grant / Funding (institution): Phosplati Therapeutics; Research grant / Funding (institution): Foundation Medicine. R.A. Soo: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self): Eli Lilly; Honoraria (self), Advisory / Consultancy: Merck Sharp & Dohme; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Taiho Pharmaceutical; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self), Advisory / Consultancy: Yuhan; Honoraria (self), Advisory / Consultancy: Celgene. D.R. Camidge: Honoraria (self): Roche; Honoraria (self): G1 Therapeutics; Honoraria (self): Mersana; Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): AstraZeneca; Honoraria (self): Genoptix; Honoraria (self): Ignyta; Honoraria (self): Daiichi Sankyo; Honoraria (self): Hansoh; Honoraria (self): Lycera; Honoraria (self): Biothera; Honoraria (self): Revolution Medicines. R. Chiari: Speaker Bureau / Expert testimony: Takeda. A. Bearz: Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Advisory / Consultancy, Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis. C. Lin: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self): Roche; Honoraria (self), Travel / Accommodation / Expenses: Daiichi Sankyo; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Blueprint Medicines; Travel / Accommodation / Expenses: Eli Lilly; Travel / Accommodation / Expenses: BeiGene. S.M. Gadgeel: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: ARIAD Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: Takeda; Research grant / Funding (self), Research grant / Funding (institution): Merck; Research grant / Funding (institution): Blueprint Medicines. E. Tan: Research grant / Funding (self): Bristol-Myers Squibb; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim. T. Seto: Honoraria (self), Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Honoraria (self), Research grant / Funding (institution): Kissei Pharmaceutical; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Nippon Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Pfizer Japan; Honoraria (self), Research grant / Funding (institution): YakultHonsha; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Kyowa Hakko Kirin; Honoraria (self): Mochida Pharmaceutical; Honoraria (self): Nippon Kayaku; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Roche Singapore; Honoraria (self): Sanofi; Honoraria (self): Showa Yakuhin Kako; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Takeda Pharmaceutical; Research grant / Funding (institution): Bayer Yakuhin; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): Novartis Pharma; Research grant / Funding (institution): Verastem. G.R. Oxnard: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Inivata; Advisory / Consultancy: Janssen; Advisory / Consultancy: Loxo; Honoraria (self): Foundation Medicine. G. Peltz: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. A. Abbattista: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. H. Thurm: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. F. Toffalorio: Shareholder / Stockholder / Stock options, Full / Part-time employment: Pfizer. S.I. Ou: Advisory / Consultancy, Shareholder / Stockholder / Stock options: TP Therapeutics; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Honoraria (self), Research grant / Funding (institution): Ariad Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Takeda; Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): AstraZeneca; Honoraria (self), Advisory / Consultancy: Foundation Medicine; Honoraria (self): Merck; Advisory / Consultancy, Research grant / Funding (institution): Ignyta; Research grant / Funding (institution): MedImmune; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Chugai Pharma; Research grant / Funding (institution): Revolution Medicines. A.T. Shaw: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Honoraria (self): Foundation Medicine; Honoraria (self): Guardant Health; Advisory / Consultancy: Roche; Advisory / Consultancy, Research grant / Funding (institution): ARIAD Pharmaceuticals; Advisory / Consultancy, Research grant / Funding (institution): Ignyta; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Taiho Pharmaceutical; Advisory / Consultancy: KSQ Therapeutics; Advisory / Consultancy: Natera; Advisory / Consultancy: Loxo Pharmaceuticals; Advisory / Consultancy: Takeda; Advisory / Consultancy: Bayer; Advisory / Consultancy: Chugai Pharma; Research grant / Funding (institution): TP Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.